The Life Sciences and Public M&A teams advised Guggenheim Securities as financial advisor to Pfizer Inc. (NYSE: PFE) in its definitive merger agreement to acquire Seagen Inc. (Nasdaq: SGEN) for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.
The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfillment of customary closing conditions, including approval of Seagen’s stockholders and receipt of required regulatory approvals.
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners.
For additional details on the acquisition, please read the merger press release.